<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0001513'>obesity</z:hpo> hormone leptin has been implicated in the development and progression of different <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> types, and preclinical studies suggest that targeting leptin signaling could be a new therapeutic option for the treatment of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, especially in <z:mp ids='MP_0001261'>obese</z:mp> patients </plain></SENT>
<SENT sid="1" pm="."><plain>To inhibit pro-neoplastic leptin activity, we developed leptin receptor (ObR) <z:chebi fb="7" ids="16670">peptide</z:chebi> <z:chebi fb="68" ids="48706">antagonists</z:chebi> capable of blocking leptin effects in vitro and in vivo </plain></SENT>
<SENT sid="2" pm="."><plain>Our lead compound (Allo-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">aca</z:e>), however, crosses the blood-brain-barrier (<z:chebi fb="2" ids="33602">BBB</z:chebi>), inducing undesirable orexigenic effects and consequent <z:mp ids='MP_0005456'>weight gain</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Thus, redesigning Allo-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">aca</z:e> to uncouple its central and peripheral activities should produce a superior compound for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatment </plain></SENT>
<SENT sid="4" pm="."><plain>The aim of this study was to generate novel Allo-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">aca</z:e> analogues and test their biodistribution in vivo and anti-neoplastic activity in vitro in breast and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells </plain></SENT>
<SENT sid="5" pm="."><plain>Examination of several Allo-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">aca</z:e> analogues resulted in the identification of the peptidomimetic,<z:chebi fb="0" ids="32843"> D-Ser</z:chebi>, that distributed only in the periphery of experimental animals </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="32843">D-Ser</z:chebi> inhibited leptin-dependent-proliferation of ObR-positive breast and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells in vitro at 1nM concentration without exhibiting any partial agonistic activity </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="32843">D-Ser</z:chebi> efficacy was demonstrated in monolayer and three-dimensional cultures, and its antiproliferative action was associated with the inhibition of several leptin-induced pathways, including JAK/STAT3, MAPK/ERK1/2 and PI3K/AKT, cyclin D1, and E-cadherin </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion,<z:chebi fb="0" ids="32843"> D-Ser</z:chebi> is the first leptin-based peptidomimetic featuring peripheral ObR antagonistic activity </plain></SENT>
<SENT sid="9" pm="."><plain>The novel <z:chebi fb="7" ids="16670">peptide</z:chebi> may serve as a prototype to develop new therapeutics, particularly for the management of <z:hpo ids='HP_0001513'>obesity</z:hpo>-related <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
</text></document>